利用结核分枝杆菌抗原特异性γ-IFN体外释放测定评估抗结核治疗疗效的临床应用价值

Practical Clinical Value of Using M.tuberculosis Antigen-Specific INF-Y Release Assay in Evaluating Anti-TB Therapeutic Result

探讨利用结核分枝杆菌抗原特异性γ-IFN体外释放测定评估抗结核治疗疗效的临床应用价值。研究了66例培养阳性肺结核病人抗结核治疗过程中抗原特异性γ-IFN体外释放测定结果的变化,并与结核菌素皮试结果的变化相比较。结果,抗原特异性γ-IFN体外释放测定于抗结核治疗前期(满2个月)的阳性率显著高于后期(疗程满6个月)[55/66(83.3%)vs12/66(18.2%);P≤0.01],而PPD结素皮试于抗结核治疗前期及后期的阳性率分别为[50/66(75.8%)vs38/66(57.6%);P>0.05]。结论:结核分枝杆菌抗原特异性γ-IFN体外释放测定评估抗结核治疗疗效较PPD结素皮试临床应用价值更大。

Practical clinical value of using M. tuberculosis antigen - specific INF - Y release assay （IGRA） in evaluating anti - TB therapeutic result was studied. The change of IGRA responses during anti - TB treatment of 66 patients with culture positive pulmonary tuberculosis was investigated, and compared with PPD tuberculin skin testing（TST）. Significantly more patients in the early （ ≤2months of anti -TB treatment）rather than the late phase （ 〉 6months ） had positive IGRA responses [ 55/66 （ 83.3 % ） vsl 2/66 （ 18.2 % ） ; P ≤ 0.01 ], comparing the patients of positive PPD results in the early （ ≤2months of anti -TB treatment） and the late phase （ 〉 6months） [ 50/66 （ 75.8 % ） vs38/66 （57.6%） ; P 〉 0.05 ]. Conclusion is that the antigen - specific INF - Y release assay has higher practical clinical value than PPD tuberculin skin testing（TST） in evaluating anti -TB therapeutic result .